A randomized phase II study comparing mFOLFOX-6 combined with axitinib or bevacizumab or both in patients with metastatic colorectal cancer (mCRC)

Authors

J Infante
A Cohn
T R. Reid
W Edenfield
Terrence P Cescon, Reading Hospital - Tower Health Department of Hematology and OncologyFollow
J Hamm
J Tarazi
S Kim
B Rosbrook
T Cartwright

Document Type

Abstract

Publication Date

1-1-2011

Publication Title

Journal of Clinical Oncology

Volume

29

Issue

4 Supplement 1

Recommended Citation

Infante, J., Cohn, A., Reid, T. R., Edenfield, W., Cescon, T., Hamm, J., Tarazi, J., Kim, S., Rosbrook, B., & Cartwright, T. (2011). A randomized phase II study comparing mFOLFOX-6 combined with axitinib or bevacizumab or both in patients with metastatic colorectal cancer (mCRC). Journal of Clinical Oncology, 29 (4 Supplement 1) Retrieved from https://scholarcommons.towerhealth.org/dept_hemonc/17